SHH Soins de santé Biotechnologie 603392.SS

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.

$ 28.54 -0.24 %

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. is a biopharmaceutical firm that handles the entire process from research and development to the production, marketing, and distribution of diagnostic solutions for infectious diseases and various vaccines. The company operates extensively across China and in international markets. Its comprehensive product range offers diagnostic test kits for a multitude of infectious agents, including COVID-19, HIV, HTLV, Hepatitis, EV-71, and Tuberculosis. It also provides specific detection reagents for Hepatitis C and Syphilis. Beyond these, the portfolio includes advanced diagnostic tools such as automated immunoassays, ELISA kits, rapid diagnostic tests, and various chemiluminescence, clinical chemistry, and general immunodiagnostic reagents. Furthermore, Beijing Wantai is a developer and supplier of vaccines for Hepatitis E and human papillomavirus (HPV). The company serves a wide array of clients, including blood banks, hospitals and clinics, specialized reference laboratories, border inspection centers, blood-processing companies, and scientific research institutes. Established in 1991, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. is headquartered in China's capital city, Beijing.

CEO: Zhiming Jiang - https://www.ystwt.com

Summary 30-Y Financials Dividend Analyst Historique indicateurs Possession / Senat
Price objectif

-

Recommandation

-

DCF

$ 2.25

Loading data...

603392.SS vs S&P500

Loading data...

No data available.

Quick ratio

3.73

suggests a healthy liquidity position, showing that the company can likely meet its short-term obligations.

P/E ratio

-95.13

may indicate that the company is undervalued or has poor growth prospects.

EPS

-0.30

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

-3.24 %

indicates low profitability, suggesting that the company is not using equity efficiently to generate profits.

ROIC

-3.13 %

does not generate enough return to cover its financing costs, which indicates value destruction and may pose long-term profitability issues.

WACC

7.42

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

0.03

indicates that the company uses more equity than debt, suggesting prudent management.

Free cash flow per share

-0.52

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

-0.43 %

indicates that the company is retaining a large portion of its profits to reinvest in growth

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
7 indicates good financial health
Altman score
13.35 indicates good financial health and low risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
1.48 indicates that the company has sufficient cash to cover its short-term debts
Debt Ratio
0.03 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.